Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthopediatrics (KIDS) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Orthopediatrics (KIDS) over the last 10 years, with Q3 2025 value amounting to -$282000.0.

  • Orthopediatrics' Cash from Financing Activities fell 10048.19% to -$282000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $23.9 million, marking a year-over-year decrease of 6217.91%. This contributed to the annual value of $53.1 million for FY2024, which is 62777.7% up from last year.
  • Per Orthopediatrics' latest filing, its Cash from Financing Activities stood at -$282000.0 for Q3 2025, which was down 10048.19% from $24.8 million recorded in Q2 2025.
  • Orthopediatrics' Cash from Financing Activities' 5-year high stood at $108.3 million during Q3 2022, with a 5-year trough of -$4.3 million in Q2 2024.
  • For the 5-year period, Orthopediatrics' Cash from Financing Activities averaged around $11.6 million, with its median value being -$33000.0 (2022).
  • The largest annual percentage gain for Orthopediatrics' Cash from Financing Activities in the last 5 years was 39022000.0% (2024), contrasted with its biggest fall of 149166.67% (2024).
  • Quarter analysis of 5 years shows Orthopediatrics' Cash from Financing Activities stood at -$34000.0 in 2021, then fell by 2.94% to -$35000.0 in 2022, then surged by 26920.0% to $9.4 million in 2023, then plummeted by 105.76% to -$541000.0 in 2024, then skyrocketed by 47.87% to -$282000.0 in 2025.
  • Its Cash from Financing Activities stands at -$282000.0 for Q3 2025, versus $24.8 million for Q2 2025 and -$126000.0 for Q1 2025.